查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070521

已批准學名藥市場規模、佔有率、成長、全球產業分析、區域趨勢以及 2026 年至 2034 年的預測。

Authorized Generics Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

已獲批准的學名藥市場成長要素

全球已核准的學名藥市場預計在2025年達到78.5億美元，從2026年的83.7億美元成長至2034年的140.8億美元，預測期內複合年成長率（CAGR）為6.71%。 2025年，北美市場佔主導地位，市場佔有率達41.78%，這主要得益於其成熟的品牌藥市場、專利保護期頻繁到期、支付方對降低成本的強烈需求以及學名藥的高滲透率。

核准的學名藥是指與品牌藥療效相當的已通過核准批准的藥物，通常由原品牌藥生產商或與其簽訂許可協議的合作公司以非專利標籤進行銷售。這些藥物有助於製藥公司在專利到期後維持一定的處方量，同時為患者提供更經濟的治療選擇。因此，核准的學名藥是品牌藥和傳統學名藥之間重要的橋樑。

市場趨勢

一個關鍵的市場趨勢是，已獲批准的學名藥擴大被納入藥品生命週期管理策略。當某種品牌藥失去壟斷地位時，原製藥公司會推出已核准的學名藥，保留原本可能落入獨立非專利競爭對手手中的市場佔有率。

這種策略使企業能夠在滿足消費者對價格合理的藥品需求的同時，維繫與支付方、藥局管道和病患的關係。例如，Lupin Pharmaceuticals於2025年10月在美國推出了其口服溶液Lavictie的核准非專利版本，這很好地體現了企業如何在品牌藥的獨家銷售期結束後利用這種模式。

市場促進因素

推動市場發展的主要因素是對低價處方藥日益成長的需求。醫療保健系統面臨降低治療成本的壓力，而核准的學名藥使得在專利到期後能夠以更低的價格銷售相同的已通過核准藥物。這提高了藥物的可及性和患者的可及性，尤其是在慢性病和成熟的治療領域。

此外，製藥公司正利用監管部門的批准和新產品的上市來強化其產品組合。梯瓦製藥於2024年6月在美國推出已核准的Victoza學名藥，凸顯了各公司正在複雜且高價值的學名藥市場拓展業務的趨勢。

市場限制因素

專利到期藥價格的快速下降正在造成市場限制。當多種低價學名藥進入市場時，價格會迅速下跌，從而降低已批准的學名藥生產商和獨立非專利非專利的盈利。

在低利潤率環境下，企業在推出新產品時可能會更加謹慎，尤其是在競爭激烈且成熟的類別中。這可能會限制產品組合的擴張，並減緩整體市場成長。

市場機遇

越來越多的品牌藥專利和獨家經銷權到期，這帶來了一個重要的機會。隨著越來越多的品牌藥失去獨家經銷權，原研藥公司可以透過推出已核准的學名藥，擴大其商業性價值，維持其處方佔有率，並提供價格更低的替代選擇。

這在患者群體龐大且處方箋頻繁的治療領域尤其重要。核准的學名藥還可以幫助支付方控制成本，同時擴大患者獲得可負擔藥物的途徑。

市場挑戰

主要挑戰在於獨家銷售期結束後激烈的價格競爭。核准的學名藥不僅要應對來自品牌藥和獨立學名藥的競爭，還要承受來自藥品福利管理機構（PBM）的價格壓力以及銷售管道的大幅折扣。這可能導致每張處方收入下降，並損害長期盈利。

因此，製造商必須謹慎選擇要推出的產品，並專注於支援永續收入的要素：需求、定價和銷售管道。

細分分析

依治療領域分類，市場可分為心血管、中樞神經系統 (CNS)、感染疾病物、腫瘤及支持性治療、內分泌及代謝、呼吸系統和其他領域。由於心血管疾病盛行率高、長期用藥依從性強、處方箋更新頻繁以及價格控制壓力大，預計到 2025 年，心血管領域將佔最大的市場佔有率。腫瘤及支持治療領域預計在預測期內將以 8.39% 的複合年成長率成長。

依給藥途徑分類，市場可分為口服、注射、外用、吸入和其他途徑。到2025年，口服給藥途徑將佔市場主導地位。這是因為口服藥物使用方便，適合長期門診治療，並且可以透過學名藥通路廣泛分銷。預計吸入給藥途徑的複合年成長率將達8.01%。

從分銷管道來看，市場細分包括零售藥局、醫院藥局、線上藥局和其他通路。預計到2025年，零售藥局將成為市場成長的主要驅動力，這主要得益於處方箋量的激增以及對慢性病治療的持續需求。線上藥局預計將以8.23%的複合年成長率成長，這主要得益於數位化藥局平台和便利的藥品取得方式。

區域分析

預計北美將引領全球市場，2025年市場規模將達32.8億美元。該地區受益於大規模的品牌藥市場、頻繁的專利到期、不斷提高的學名藥滲透率以及支付方對具成本效益藥物的強勁需求。美國市場預計到2026年將達到32.4億美元，約佔全球銷售額的38.70%。

在政府定價機制、替代藥品引進框架以及學名藥廣泛普及的支持下，預計到 2026 年，歐洲藥品市場規模將達到 19.8 億美元。德國預計將達到 4.2 億美元，而英國預計到 2026 年將達到 3.8 億美元。

預計到2026年，亞太地區市場規模將達到16億美元，主要得益於降低藥品價格的政策以及慢性病負擔日益加重。其中，印度市場規模預估為4.7億美元，中國為3.8億美元，日本為2.3億美元。

預計到2026年，拉丁美洲市場規模將達到6.3億美元，而中東和非洲的海灣合作理事會市場規模預計將達到2.5億美元。南非市場預計到2026年將達到1.1億美元。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 2025年市場上已獲批准的學名藥概覽
  • 主要地區和國家主要疾病的流行情況
  • 新產品發布：按主要公司分類
  • 主要產業趨勢（合併、收購、合作、新產品和服務的推出等）

第5章：2021-2034年全球已批准學名藥市場分析、洞察與預測

  • 市場分析、洞察與預測：按治療領域分類
    • 心血管系統
    • CNS
    • 抗感染藥物
    • 腫瘤科及支持性治療
    • 內分泌/代謝
    • 呼吸系統
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 腸外
    • 外用
    • 吸入
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 零售藥房
    • 醫院藥房
    • 網路藥房
    • 其他
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美獲準學名藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：2021-2034年歐洲已批准學名藥市場分析、洞察與預測

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區已批准學名藥市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：2021-2034年拉丁美洲已批准學名藥市場分析、洞察與預測

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：2021-2034年中東和非洲已批准學名藥市場分析、洞察與預測

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Prasco, LLC
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz AG
    • Pfizer Inc.（via Greenstone）
    • Lupin Limited
    • Hikma Pharmaceuticals PLC
    • Amneal Pharmaceuticals, Inc.
    • Padagis LLC
    • GSK plc
    • Viatris Inc.
Product Code: FBI116057

Growth Factors of Authorized Generics Market

The global Authorized Generics Market was valued at USD 7.85 billion in 2025 and is projected to grow from USD 8.37 billion in 2026 to USD 14.08 billion by 2034, exhibiting a CAGR of 6.71% during the forecast period. North America dominated the market in 2025 with a 41.78% share, supported by mature branded-drug markets, frequent loss-of-exclusivity events, strong payer focus on cost savings, and high generic medicine adoption.

Authorized generics are approved brand-equivalent medicines launched under a generic label, usually by the original brand manufacturer or through a licensed partner. They help pharmaceutical companies protect part of their prescription volume after patent expiry while offering patients lower-cost treatment options. This makes authorized generics an important bridge between branded drugs and traditional generics.

Market Trends

A major trend in the market is the rising use of authorized generics as a pharmaceutical lifecycle management strategy. When branded medicines lose exclusivity, originator companies launch authorized generic versions to retain part of the market that would otherwise shift to independent generic competitors.

This strategy helps companies maintain relationships with payers, pharmacy channels, and patients while responding to demand for affordable medicines. For example, Lupin launched an authorized generic version of Ravicti Oral Liquid in the U.S. in October 2025, showing how companies are using this model after branded drug exclusivity periods.

Market Drivers

The main market driver is growing demand for lower-cost prescription medicines. Healthcare systems are under pressure to reduce treatment spending, and authorized generics allow the same approved medicines to be sold at lower prices after patent expiry. This improves affordability and patient access, especially in chronic and mature therapy areas.

Pharmaceutical companies are also using regulatory approvals and new launches to strengthen their portfolios. Teva's launch of an authorized generic of Victoza in the U.S. in June 2024 highlights how companies are expanding in complex and high-value generic categories.

Market Restraints

The market faces restraints due to rapid price erosion in off-patent drug categories. When several low-cost versions of a medicine enter the market, prices decline quickly, reducing profitability for both authorized generic and independent generic manufacturers.

Thin margins may make companies more selective about launches, especially in mature categories with intense competition. This can limit portfolio expansion and slow overall market growth.

Market Opportunities

A key opportunity is the growing number of branded drugs reaching the end of patent or exclusivity protection. As more branded medicines lose exclusivity, originator companies can launch authorized generics to extend commercial value, retain prescription share, and provide lower-cost alternatives.

This is especially important in therapy areas with large patient populations and recurring prescriptions. Authorized generics can also support payer cost-control strategies while expanding affordable access for patients.

Market Challenges

The major challenge is steep post-exclusivity price competition. Authorized generics compete with branded products, independent generics, pharmacy benefit manager pricing pressure, and aggressive channel discounting. This lowers revenue per prescription and can reduce long-term profitability.

As a result, manufacturers must carefully choose which products to launch, focusing on molecules where demand volume, pricing, and channel access support sustainable returns.

Segmentation Analysis

By therapy area, the market is segmented into cardiovascular, CNS, anti-infectives, oncology & supportive care, endocrine & metabolic, respiratory, and others. The cardiovascular segment held the largest market share in 2025 due to high disease prevalence, long-term medication use, recurring refills, and strong affordability pressure. The oncology & supportive care segment is expected to grow at a CAGR of 8.39% during the forecast period.

By route of administration, the market is divided into oral, parenteral, topical, inhalation, and others. The oral segment dominated in 2025 because oral medicines are easier to use, suitable for long-term outpatient therapy, and widely distributed through generic channels. The inhalation segment is projected to grow at a CAGR of 8.01%.

By distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, online pharmacies, and others. Retail pharmacies led the market in 2025 due to high outpatient prescription volume and recurring demand for chronic therapies. The online pharmacies segment is expected to grow at a CAGR of 8.23%, supported by digital pharmacy platforms and convenience-based medicine access.

Regional Analysis

North America led the global market with USD 3.28 billion in 2025. The region benefits from large branded-drug markets, frequent patent expiries, mature generic adoption, and strong payer demand for cost-effective medicines. The U.S. market is estimated at USD 3.24 billion in 2026, accounting for around 38.70% of global revenue.

Europe is projected to reach USD 1.98 billion in 2026, supported by government pricing systems, substitution frameworks, and generic medicine adoption. Germany is expected to reach USD 0.42 billion, while the U.K. is estimated at USD 0.38 billion in 2026.

Asia Pacific is estimated to reach USD 1.60 billion in 2026, driven by cheaper medicine access policies and rising chronic disease burden. India is estimated at USD 0.47 billion, China at USD 0.38 billion, and Japan at USD 0.23 billion in 2026.

Latin America is expected to reach USD 0.63 billion in 2026, while the GCC market in the Middle East & Africa is projected at USD 0.25 billion in 2026. South Africa is estimated at USD 0.11 billion in 2026.

Competitive Landscape

The market is highly consolidated, with leading companies focusing on product launches, partnerships, licensing, and portfolio expansion. Key players include Prasco, LLC, Teva Pharmaceutical Industries Ltd., Sandoz AG, Pfizer Inc., Lupin Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, Padagis LLC, GSK plc, and Viatris Inc.

Key Industry Developments

In April 2026, Accord Healthcare re-launched Hydrochlorothiazide Tablets in multiple strengths. In February 2026, Lupin launched the authorized generic version of Apriso in the U.S. In December 2025, Amneal received U.S. FDA approval for albuterol sulfate inhalation aerosol. In November 2022, Prasco launched the authorized generic of ZIOPTAN. In March 2021, Sandoz in-licensed commercial distribution rights for Proventil HFA.

Conclusion

The authorized generics market is expected to grow from USD 7.85 billion in 2025 to USD 8.37 billion in 2026 and reach USD 14.08 billion by 2034. Growth will be driven by patent expiries, demand for lower-cost medicines, payer cost-control efforts, and lifecycle management strategies. Despite price erosion and intense post-exclusivity competition, authorized generics will remain important for improving medicine affordability and preserving brand-linked market value.

Segmentation By Therapy Area, Route of Administration, Distribution Channel, and Region

By Therapy Area * Cardiovascular

  • CNS
  • Anti-infectives
  • Oncology & Supportive Care
  • Endocrine & Metabolic
  • Respiratory
  • Others

By Route of Administration * Oral

  • Parenteral
  • Topical
  • Inhalation
  • Others

By Distribution Channel * Retail Pharmacies

  • Hospital Pharmacies
  • Online Pharmacies
  • Others

By Region * North America (By Therapy Area, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Therapy Area, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Therapy Area, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Therapy Area, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Therapy Area, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Authorized Generics in the Market, 2025
  • 4.2. Prevalence of Key Diseases, By Key Regions/ Countries
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Authorized Generics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 5.1.1. Cardiovascular
    • 5.1.2. CNS
    • 5.1.3. Anti-infectives
    • 5.1.4. Oncology & Supportive Care
    • 5.1.5. Endocrine & Metabolic
    • 5.1.6. Respiratory
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
    • 5.2.3. Topical
    • 5.2.4. Inhalation
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Retail Pharmacies
    • 5.3.2. Hospital Pharmacies
    • 5.3.3. Online Pharmacies
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Authorized Generics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 6.1.1. Cardiovascular
    • 6.1.2. CNS
    • 6.1.3. Anti-infectives
    • 6.1.4. Oncology & Supportive Care
    • 6.1.5. Endocrine & Metabolic
    • 6.1.6. Respiratory
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
    • 6.2.3. Topical
    • 6.2.4. Inhalation
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Retail Pharmacies
    • 6.3.2. Hospital Pharmacies
    • 6.3.3. Online Pharmacies
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Authorized Generics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 7.1.1. Cardiovascular
    • 7.1.2. CNS
    • 7.1.3. Anti-infectives
    • 7.1.4. Oncology & Supportive Care
    • 7.1.5. Endocrine & Metabolic
    • 7.1.6. Respiratory
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
    • 7.2.3. Topical
    • 7.2.4. Inhalation
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Retail Pharmacies
    • 7.3.2. Hospital Pharmacies
    • 7.3.3. Online Pharmacies
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Authorized Generics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 8.1.1. Cardiovascular
    • 8.1.2. CNS
    • 8.1.3. Anti-infectives
    • 8.1.4. Oncology & Supportive Care
    • 8.1.5. Endocrine & Metabolic
    • 8.1.6. Respiratory
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
    • 8.2.3. Topical
    • 8.2.4. Inhalation
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Retail Pharmacies
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Southeast Asia
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Authorized Generics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 9.1.1. Cardiovascular
    • 9.1.2. CNS
    • 9.1.3. Anti-infectives
    • 9.1.4. Oncology & Supportive Care
    • 9.1.5. Endocrine & Metabolic
    • 9.1.6. Respiratory
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
    • 9.2.3. Topical
    • 9.2.4. Inhalation
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Retail Pharmacies
    • 9.3.2. Hospital Pharmacies
    • 9.3.3. Online Pharmacies
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Authorized Generics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Therapy Area
    • 10.1.1. Cardiovascular
    • 10.1.2. CNS
    • 10.1.3. Anti-infectives
    • 10.1.4. Oncology & Supportive Care
    • 10.1.5. Endocrine & Metabolic
    • 10.1.6. Respiratory
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
    • 10.2.3. Topical
    • 10.2.4. Inhalation
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Retail Pharmacies
    • 10.3.2. Hospital Pharmacies
    • 10.3.3. Online Pharmacies
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Prasco, LLC
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
    • 11.2.3. Sandoz AG
    • 11.2.4. Pfizer Inc. (via Greenstone)
    • 11.2.5. Lupin Limited
    • 11.2.6. Hikma Pharmaceuticals PLC
    • 11.2.7. Amneal Pharmaceuticals, Inc.
    • 11.2.8. Padagis LLC
    • 11.2.9. GSK plc
    • 11.2.10. Viatris Inc.

List of Tables

  • Figure 1: Global Authorized Generics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Authorized Generics Market Value Share (%), by Therapy Area, 2025 & 2034
  • Figure 3: Global Authorized Generics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Authorized Generics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Authorized Generics Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Authorized Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 7: North America Authorized Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 8: North America Authorized Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Authorized Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Authorized Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Authorized Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Authorized Generics Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Authorized Generics Market Value Share (%), by Country, 2025
  • Figure 14: Europe Authorized Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 15: Europe Authorized Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 16: Europe Authorized Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Authorized Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Authorized Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Authorized Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Authorized Generics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Authorized Generics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Authorized Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 23: Asia Pacific Authorized Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 24: Asia Pacific Authorized Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Authorized Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Authorized Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Authorized Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Authorized Generics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Authorized Generics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Authorized Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 31: Latin America Authorized Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 32: Latin America Authorized Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Authorized Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Authorized Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Authorized Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Authorized Generics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Authorized Generics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Authorized Generics Market Value (USD billion), by Therapy Area, 2025 & 2034
  • Figure 39: Middle East & Africa Authorized Generics Market Value Share (%), by Therapy Area, 2025
  • Figure 40: Middle East & Africa Authorized Generics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Authorized Generics Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Authorized Generics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Authorized Generics Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Authorized Generics Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Authorized Generics Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Authorized Generics Market Share (%), by Company, 2025